SCHEMBL393159

SCHEMBL393159

Cc1nnc(-c2cn(C)c(=O)c(F)c2Nc2ccc(Br)cc2F)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 19/20 0.57
MAP2K2 P36507 1/20 0.41
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391990 0.89 MAP2K1 (0.58) MAP2K1MAP2K2ALOX15TSHR
SCHEMBL15700930 0.79 MAP2K1 (0.70) MAP2K1MAP2K2ALOX15TSHR
SCHEMBL391367 0.77 MAP2K1 (0.59) MAP2K1MAP2K2ALOX15TSHR
SCHEMBL393120 0.77 MAP2K1 (0.58) MAP2K1MAP2K2ALOX15TSHR
SCHEMBL12899190 0.77 MAP2K1 (0.43) MAP2K1
SCHEMBL391996 0.77 MAP2K1 (0.53) MAP2K1MAP2K2ALOX15TSHR
SCHEMBL1516547 0.76 MAP2K1 (0.71) MAP2K1MAP2K2ALOX15TSHR
SCHEMBL10195311 0.75 MAP2K1 (0.54) MAP2K1MAP2K2
Hydrochloric Acid SCHEMBL388702 0.74 MAP2K1 (0.53) MAP2K1MAP2K2
SCHEMBL1516511 0.74 MAP2K1 (0.64) MAP2K1MAP2K2ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268852-B2 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. (US) 2012-09-18 US claimed
US-20090143579-A1 Heterocyclic Inhibitors of MEK and Methods of Use Thereof ARRAY BIOPHARMA INC. (US) 2009-06-04 US claimed
US-20080251411-A1 Lid Sheet For Use in a Blister Pack ALCAN TECHNOLOGY & MANAGEMENT LTD. (CH) 2008-10-16 US claimed
EP-1928654-A2 LID SHEET FOR USE IN A BLISTER PACK GLAXO GROUP LIMITED (GB) 2008-06-11 EP claimed
WO-2007038488-A2 LID SHEET FOR USE IN A BLISTER PACK GLAXO GROUP LIMITED (GB) 2007-04-05 WO claimed
US-7017628-B2 Ecologically friendly funnel CALIFORNIA PACIFIC LAB, INC. (US) 2006-03-28 US claimed
US-20050263210-A1 Ecologically friendly funnel CALIFORNIA PACIFIC LAB, INC. 2005-12-01 US claimed
WO-2019112138-A1 METHOD FOR PREPARING BIO-FILLER TO BE ADDED TO PLASTIC, AND BIO-FILLER TO BE ADDED TO PLASTIC, PREPARED THEREBY 주식회사 리그넘 2019-06-13 WO disclosed
EP-2251327-B1 HETEROCYCLIC INHIBITORS OF MEK ARRAY BIOPHARMA INC (US) 2014-02-12 EP disclosed
EP-2251327-B1 HETEROCYCLIC INHIBITORS OF MEK ARRAY BIOPHARMA INC (US) 2014-02-12 EP disclosed
CN-103333162-A Viral polymerase inhibitors BOEHRINGER INGELHEIM INT 2013-10-02 CN disclosed
CN-103319464-A Viral polymerase inhibitors BOEHRINGER INGELHEIM INT 2013-09-25 CN disclosed
CN-103304541-A Viral polymerase inhibitors BOEHRINGER INGELHEIM INT 2013-09-18 CN disclosed
US-7017628-B2 Ecologically friendly funnel CALIFORNIA PACIFIC LAB, INC. (US) 2006-03-28 US disclosed
US-20050263210-A1 Ecologically friendly funnel CALIFORNIA PACIFIC LAB, INC. 2005-12-01 US disclosed
US-20050256123-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2005-11-17 US disclosed
US-20050250782-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2005-11-10 US disclosed
WO-2005051301-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2005-06-09 WO disclosed
US-20020192036-A1 Erosion control mats HEI LLC 2002-12-19 US disclosed
US-4874656-A POLYESTER, POLYPROPYLENE, AND METALLIC FOIL; VAPOR AND GAS IMPERMEABILITY; FIREARMS A. AHLSTRON CORPORATION (FI) 1989-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250782-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, MAPK9 MAP2K1 87/4885MAP2K2 73/4885ALOX15 1476/4885
US-20090143579-A1 Heterocyclic Inhibitors of MEK and Methods of Use Thereof NRAS, BRAF, MAPK9 MAP2K1 85/4885MAP2K2 69/4885ALOX15 1593/4885
US-20050256123-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, MAPK9 MAP2K1 82/4885MAP2K2 69/4885ALOX15 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.